Reata Pharmaceuticals, Inc.
RETA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $2 | $11 | $9 | $27 |
| % Growth | -80.7% | 27.4% | -66% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $124 |
| Gross Profit | $2 | $11 | $9 | -$98 |
| % Margin | 100% | 100% | 100% | -369.1% |
| R&D Expenses | $170 | $156 | $159 | $128 |
| G&A Expenses | $109 | $99 | $75 | $58 |
| SG&A Expenses | $109 | $99 | $75 | $58 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Expenses | $280 | $256 | $235 | $187 |
| Operating Income | -$270 | -$245 | -$226 | -$285 |
| % Margin | -12,191.1% | -2,129.7% | -2,509.4% | -1,075.6% |
| Other Income/Exp. Net | -$34 | -$53 | -$44 | -$5 |
| Pre-Tax Income | -$312 | -$298 | -$270 | -$290 |
| Tax Expense | -$0 | -$0 | -$22 | $0 |
| Net Income | -$312 | -$297 | -$248 | -$290 |
| % Margin | -14,075% | -2,588.2% | -2,747% | -1,094.3% |
| EPS | -8.59 | -8.19 | -7.35 | -9.54 |
| % Growth | -4.9% | -11.4% | 23% | – |
| EPS Diluted | -8.59 | -8.19 | -7.35 | -9.54 |
| Weighted Avg Shares Out | 36 | 36 | 34 | 30 |
| Weighted Avg Shares Out Dil | 36 | 36 | 34 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $0 | $0 | $0 |
| Interest Expense | $42 | $53 | $37 | $11 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$269 | -$244 | -$232 | -$278 |
| % Margin | -12,140.1% | -2,119.3% | -2,575.9% | -1,048.5% |